BioHarvest Sciences Inc., a company specializing in Botanical Synthesis technology, reported a significant increase in its first quarter 2025 financial results. Revenues surged by 47% year-over-year to $7.9 million, surpassing management's guidance. This growth was primarily driven by the success of the VINIA® product line, which expanded its active subscriber base to over 50,000 as of February 2025. Gross profit for the quarter rose by 53% to $4.6 million, representing 58.5% of total revenue, compared to $3.0 million or 56.2% in the same period the previous year. The improvement in gross margin was attributed to enhanced manufacturing scale and yields. Looking forward, BioHarvest anticipates continued expansion in its Products and Services business units, aiming to grow the "VINIA® inside" product lines and subscriber bases, along with adding new CDMO partners. The company remains focused on leveraging its Botanical Synthesis platform to meet rising global consumer health and wellness trends.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。